According to GlobalData’s medical device pipeline database, 34 COVID-19 Other Tests devices are in various stages of development globally. GlobalData’s report COVID-19 Other Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 32 are in active development, while the remaining two are in an inactive stage of development. There are 15 products in the early stages of development, and the remaining 17 are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. COVID-19 Other Tests includes diagnostic tests that are not part of COVID-19 NAATs and COVID-19 Immunoassay tests.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed COVID-19 Other Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of COVID-19 Other Tests devices. Overall, most of these COVID-19 Other Tests pipeline devices are being developed by private entities.
Key players involved in the active development of COVID-19 Other Tests include IncellDx, Indian Council of Medical Research, Inherent Biosciences, LifeVault Bio, Molbio Diagnostics, Nanohmics, Nanostics, Nightingale Health, ProAxsis and Royal College of Surgeons Ireland.
For a complete picture of the developmental pipeline for COVID-19 Other Tests devices, buy the report here.